Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

HIV: Update Bulletin [August 2014]

Product Code:
596200301
Release Date:
August 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in HIV: ViiV Healthcare’s Tivicay and Triumeq, Merck & Co.’s, Isentress, raltegravir/lamivudine, Gilead’s Vitekta, Tybost, Janssen, Gilead’s, Prezista/cobicistat

Highlights from this event update bulletin

  • Optimism for ViiV Healthcare’s Tivicay continues post launch
  • ViiV Healthcare’s Triumeq has raised the bar for single-pill complete regimens
  • Abacavir component in Triumeq may be its only drawback
  • New once-daily formulation of Merck & Co.’s Isentress may improve its performance
  • Gilead resubmits NDAs for standalone elvitegravir and cobicistat
  • The future of Janssen and Gilead’s Prezista-cobicistat FDC is uncertain
  • Pessimism for Merck & Co.’s FDC of raltegravir plus lamivudine

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved